Company intelligence / Profile preview

Blade Therapeutics, Inc.

South San Francisco, California, United Statesleadiq.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Blade Therapeutics has completed four Phase 1 studies of cudetaxestat (BLD-0409) in more than 200 healthy volunteers, showing it was well tolerated with demonstrated pharmacokinetic/pharmacodynamic correlation and biomarker activity. The FDA has provided feedback necessary to proceed into a Phase 2 proof of concept/dose ranging study for idiopathic pulmonary fibrosis (IPF).

Therapeutic areas: GastroenterologyPulmonologyRare DiseasesNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

cudetaxestat

4 more assets in the full pipeline.

Request access →

Partnerships

Biotech Acquisition Company (merger agreement was terminated in June 2022)

Beyond the preview

Go deeper on Blade Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blade Therapeutics, Inc..

Explore the full profile